Kalaris Therapeutics Appoints New Director, Updates Executive Compensation
Ticker: KLRS · Form: 8-K · Filed: Apr 4, 2025 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Kalaris Therapeutics, Inc. (KLRS) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation
TL;DR
Kalaris adds a director and revises exec pay. New roles for Brown & Deitcher.
AI Summary
Kalaris Therapeutics, Inc. announced on April 3, 2025, changes in its board of directors and executive compensation. Specifically, Dr. David L. Brown was appointed as a Class II Director, and the company entered into new employment agreements with its Chief Executive Officer, Dr. David L. Brown, and Chief Medical Officer, Dr. Steven M. Deitcher, effective April 3, 2025.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or leadership focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directorship and executive compensation can indicate internal shifts that may affect the company's future direction and stability.
Key Players & Entities
- Kalaris Therapeutics, Inc. (company) — Registrant
- David L. Brown (person) — Class II Director and CEO
- Steven M. Deitcher (person) — Chief Medical Officer
- April 3, 2025 (date) — Effective date of changes
FAQ
Who was appointed as a new director for Kalaris Therapeutics, Inc.?
Dr. David L. Brown was appointed as a Class II Director.
What is the effective date of the reported changes?
The earliest event reported is dated April 3, 2025.
What specific executive roles are mentioned in the filing regarding new agreements?
The filing mentions new employment agreements for the Chief Executive Officer and the Chief Medical Officer.
What is the principal executive office address for Kalaris Therapeutics, Inc.?
The principal executive offices are located at 628 Middlefield Rd., Palo Alto, California 94301.
What is the Commission File Number for Kalaris Therapeutics, Inc.?
The Commission File Number is 001-39409.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 4, 2025 by David L. Brown regarding Kalaris Therapeutics, Inc. (KLRS).